HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Bloomgarden, Z. T. PubMed PubMed Citation Articles by Bloomgarden, Z. T. Social Bookmarking                What's this?

Diabetic Retinopathy

Zachary T. Bloomgarden, MD, is a practicing endocrinologist in New York, New York, and is affiliated with the Division of Endocrinology, Mount Sinai School of Medicine, New York, New York

Abbreviations: DCCT, Diabetes Control and Complications Trial • UKPDS, UK Prospective Diabetes Study

The first 300 words of the full text of this article appear below.

Perspectives on the News commentaries are part of a free monthly CME activity. The Mount Sinai School of Medicine, New York, New York, designates this activity for 2.0 AMA PRA Category 1 credits. If you wish to participate, review this article and visit www.diabetes.procampus.net to complete a posttest and receive a certificate. The Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This is the ninth in a series of articles based on presentations at the American Diabetes Association's 67th Scientific Sessions, 22–26 June 2007, Chicago, Illinois, that discuss aspects of diabetic retinopathy.

A number of studies presented at the ADA meeting addressed aspects of the clinical epidemiology of diabetic eye disease. Saaddine et al. (abstract 819) used National Health Interview Survey and census data to project that the prevalence of diabetic retinopathy in the U.S. will increase from 5.8 to 17.7 million people from 2005 to 2050, with retinopathy threatening vision projected to increase from 1.3 to 3.7 million over this time. (Abstract numbers refer to the American Diabetes Association Scientific Sessions, Diabetes 56 [Suppl. 1], 2007.) Cataracts, Saaddine reported, will likely more than double in prevalence, and there will be a 12-fold increase in the number of Hispanics with diabetes 65 years old who have glaucoma.

Emanuele et al. (abstract 95) reported the presence of clinically significant macular edema in 11% of 536 diabetic individuals, with prevalence more than twice as great in Hispanic and African-American as that in non-Hispanic White patients. In multivariate analysis, diastolic blood pressure, duration of diabetes, and the urine albumin-to-creatinine ratio were additional contributory factors. Sibal and Home (abstract 832) studied 404 type 1 diabetic patients followed for 9 years, finding retinopathy to be associated with higher diastolic . . . [Full Text of this Article]

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?